These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38605549)

  • 1. Unlocking PD-1 antibody resistance: The MUC1 DNA vaccine augments CD8
    Wang X; Miao Y; Shen J; Li D; Deng X; Yang C; Ji Y; Dai Z; Ma Y
    Scand J Immunol; 2024 May; 99(5):e13356. PubMed ID: 38605549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evodiamine suppresses non-small cell lung cancer by elevating CD8
    Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
    J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
    Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
    J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
    Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 9. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
    Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
    EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer.
    Guo M; Luo B; Pan M; Li M; Xu H; Zhao F; Dou J
    Int Immunopharmacol; 2020 Nov; 88():106850. PubMed ID: 32777675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
    Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
    Front Immunol; 2019; 10():1939. PubMed ID: 31475002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.
    Liu C; Lu Z; Xie Y; Guo Q; Geng F; Sun B; Wu H; Yu B; Wu J; Zhang H; Yu X; Kong W
    Immunol Lett; 2018 Aug; 200():33-42. PubMed ID: 29894719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant.
    Ruan J; Duan Y; Li F; Wang Z
    Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):71-78. PubMed ID: 27562635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.
    Luchtel RA; Bhagat T; Pradhan K; Jacobs WR; Levine M; Verma A; Shenoy N
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1666-1677. PubMed ID: 31911474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model.
    Bahwal SA; Chen JJ; E L; Hao T; Chen J; Carruthers VB; Lai J; Zhou X
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2743-2757. PubMed ID: 35556163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
    Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
    Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8
    Tichet M; Wullschleger S; Chryplewicz A; Fournier N; Marcone R; Kauzlaric A; Homicsko K; Deak LC; Umaña P; Klein C; Hanahan D
    Immunity; 2023 Jan; 56(1):162-179.e6. PubMed ID: 36630914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.